Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New surgical order may boost pancreatic cancer outcomes

NCT ID NCT07547033

Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether changing the order of steps during a Whipple surgery for pancreatic head cancer can help surgeons remove the tumor more completely and lower the chance of cancer coming back. About 150 adults with operable pancreatic cancer will be randomly assigned to either the standard surgery or the newer 'artery-first' technique. The main goal is to see if the artery-first approach leads to clearer surgical margins, which may improve long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Primary resectable or borderline with isolated veinous contact pancreatic adenocarcinoma (according to the NCCN classification and international consensual definition of Isaji 2018): resectability is evaluated on arterial-phase and portal-phase IV contrast-enhanced multislice CT scan of the pancreas (slice thickness: 2.5 mm), and assessed in a multidisciplinary staff meeting including at least one radiologist and one expert surgeon. 2. CT-scan of the thorax and abdomen confirming non-metastatic PAC at least 45 days before inclusion 3. MRI of the liver without metastasis performed maximum one month before inclusion 4. CA 19.9 (carbohydrate antigen) level ≤ 500 U/mL at the time of inclusion (in absence of cholestasis or biliary drainage) 5. Age 18 or over 6. Grade 0 or 1 Performans Status (ECOG) 7. Normal renal and liver function at the time of inclusion (According to Cockroft and Gault's equation Glomerular Function Rate \> 50ml/min/m2; Prothrombin Time \> 70%) 8. Absolute neutrophil count \> 1,500/mm3, platelet count \> 100,000/mm3, haemoglobin level \> 10 g/dl (transfusions are authorized) at time of inclusion 9. Adequate contraception on fertile women 10. "Women of childbearing potential (defined as under 50 years of age and without a history of hysterectomy or tubal ligation) must not self-report being pregnant on the day of inclusion." 11. Patient who provides a signed written informed consent form 12. Patient having the rights to French social insurance Exclusion Criteria: 1. Pancreatic adenocarcinoma defined as "borderline" with arterial contact, locally advanced, non-resectable, or metastatic. 2. Surgical or anesthesiologic contra-indications: Non-controlled congestive heart failure - non-treated angina - recent myocardial infarction (in the previous year) - non-controlled AHT (SBP \>160 mm or DBP \> 100 mm, despite optimal drug treatment), long QT 3. Major non-controlled infection 4. Major comorbidity that may preclude the surgery 5. Severe liver failure 6. Any medical, psychological, or social situation that (in the investigator's opinion) could limit (i) the patient's compliance with the protocol or (ii) the ability to obtain or interpret data 7. Pregnant or breastfeeding women and women of childbearing age not using effective means of contraception 8. Curatorship or guardianship or patient placed under judicial protection 9. Participation in other interventional research type 1, clinical investigation or clinical trial during the study Secondary exclusion criterion (during surgery): 1. Evaluation of abdominal cavity, presenting infra-radiologic metastasis 2. Positive tumoral invasion at frozen section after picking on the inter-aortic lymph nodes performed before any irrevocable organ section. 3. Anasthaesiologic complication (induction allergy or unprevisible heart disease at induction) 4. For fertile women: serological pregnancy test positive before surgery

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pancreatic adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma pancreatic adenocarcinoma pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreatic adenocarcinoma Pancreatic head cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    23 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU Amiens

    Amiens, France

  • CHU Angers

    Angers, France

  • CHU Besançon

    Besançon, France

  • CHU Dupuytren 1

    Limoges, France

  • CHU Lille - Hôpital Claude Huriez

    Lille, France

  • CHU Strasbourg

    Strasbourg, France

  • Centre Léon Bérard

    Lyon, France

  • Chu Nantes

    Nantes, France

  • Hôpital Ambroise Paré

    Paris, France

  • Hôpital Beaujon

    Paris, France

  • Hôpital Charles-Nicolle

    Rouen, France

  • Hôpital Claude Huriez

    Lille, France

  • Hôpital Cochin

    Paris, France

  • Hôpital Estaing

    Clermont-Ferrand, France

  • Hôpital François Mitterrand

    Dijon, France

  • Hôpital Haut Lévêque

    Bordeaux, France

  • Hôpital Paul Brousse

    Villejuif, France

  • Hôpital Rangueil

    Toulouse, France

  • Hôpital Saint Eloi

    Montpellier, France

  • Hôpital de la Croix-Rousse

    Lyon, France

  • Hôpital de la Pitié Salpêtrière

    Paris, France

  • Hôpitaux de Brabois

    Nancy, France

  • Institut Gustave Roussy

    Villejuif, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.